Japan has granted an emergency approval to Chugai/Roche/Regeneron's antibody cocktail after a rapid review, while India has emerged as one of the top purchasers globally of COVID-19 vaccines as it looks to protect more of its population. 

In this week's podcast edition of Five Must-Know Things: pharma’s Q2 prospects; Bayer’s plans for the US launch of its CKD drug; big tobacco takes further steps into healthcare; KRAS’s emergence in oncology amid ongoing challenges; and tips for European biotech fundraising.

In this week's podcast edition of Five Must-Know Things: Novartis’s US strategy for inclisiran; Roche under pressure over prices for Actemra in COVID; Lambda coronavirus variant poses new challenge for vaccines; GSK loses its oncology R&D head; and a look at expected Q3 approvals in the US.

Plus deals involving Y-Biologics/Pierre Fabre, Contera/Abzu, Chugai/Alebund, Catalyst/DyDo, Spergogenix/Abbiska, Nippon Gene/ERS Genomics, Simcere/Vivoryon, Dr. Reddy’s/Journey Medical and Innovent/Synaffix.

Given its ever-growing role as a critical region for the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.

In this week's podcast edition of Five Must-Know Things: vaccine efficacy and the Delta and Delta Plus variants; breakthroughs in CRISPR gene editing and microbiome therapies; and the pandemic’s possible effect on regulatory pathways.